XML 157 R111.htm IDEA: XBRL DOCUMENT v3.24.0.1
Goodwill and other intangible assets - Detailed Information for Principal Marketed Products (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 24,319 € 21,640 € 21,407
Marketed products      
Disclosure of detailed information about intangible assets [line items]      
Concentration risk percentage 96.00%    
Other intangible assets € 16,600 12,700 11,700
Useful life, intangible assets other than goodwill (in years) 11 years    
Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 15,927 11,863 10,752
Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 208 621 1,032
Useful life, intangible assets other than goodwill (in years) 10 years    
Remaining amortisation period of intangible assets material to entity 2 years    
Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,806 2,037 2,213
Useful life, intangible assets other than goodwill (in years) 17 years    
Remaining amortisation period of intangible assets material to entity 11 years    
Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 43 58 73
Useful life, intangible assets other than goodwill (in years) 9 years    
Remaining amortisation period of intangible assets material to entity 11 years    
Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 501 574 593
Useful life, intangible assets other than goodwill (in years) 23 years    
Remaining amortisation period of intangible assets material to entity 10 years    
Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 420 498 532
Useful life, intangible assets other than goodwill (in years) 13 years    
Remaining amortisation period of intangible assets material to entity 7 years    
Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,220 1,357 1,494
Useful life, intangible assets other than goodwill (in years) 14 years    
Remaining amortisation period of intangible assets material to entity 9 years    
Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 5,152 4,836 3,065
Useful life, intangible assets other than goodwill (in years) 14 years    
Remaining amortisation period of intangible assets material to entity 9 years    
REZUROCK      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,580 1,702 1,750
Useful life, intangible assets other than goodwill (in years) 12 years    
Remaining amortisation period of intangible assets material to entity 10 years    
TZIELD      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 2,405 0 0
Useful life, intangible assets other than goodwill (in years) 12 years    
Remaining amortisation period of intangible assets material to entity 12 years    
BEYFORTUS      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 1,870 180 0
Useful life, intangible assets other than goodwill (in years) 18 years    
Remaining amortisation period of intangible assets material to entity 17 years    
QUNOL      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 722 € 0 € 0
Useful life, intangible assets other than goodwill (in years) 10 years    
Remaining amortisation period of intangible assets material to entity 9 years    
Gross value | Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € 66,880    
Gross value | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 10,279    
Gross value | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 3,504    
Gross value | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 33,043    
Gross value | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,319    
Gross value | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 831    
Gross value | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,966    
Gross value | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 8,798    
Gross value | REZUROCK      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,907    
Gross value | TZIELD      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 2,546    
Gross value | BEYFORTUS      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 1,946    
Gross value | QUNOL      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets 741    
Accumulated amortization & impairment | Total: principal marketed products      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (50,953)    
Accumulated amortization & impairment | Genzyme      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (10,071)    
Accumulated amortization & impairment | Boehringer Ingelheim Consumer Healthcare      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (1,698)    
Accumulated amortization & impairment | Aventis      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (33,000)    
Accumulated amortization & impairment | Chattem      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (818)    
Accumulated amortization & impairment | Protein Sciences      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (411)    
Accumulated amortization & impairment | Ablynx      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (746)    
Accumulated amortization & impairment | Bioverativ      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (3,646)    
Accumulated amortization & impairment | REZUROCK      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (327)    
Accumulated amortization & impairment | TZIELD      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (141)    
Accumulated amortization & impairment | BEYFORTUS      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets (76)    
Accumulated amortization & impairment | QUNOL      
Disclosure of detailed information about intangible assets [line items]      
Other intangible assets € (19)    
Bottom of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 1 year    
Top of range      
Disclosure of detailed information about intangible assets [line items]      
Useful life, intangible assets other than goodwill (in years) 25 years